ライフサイエンスコーパス: melatonin receptor

1 consistent with its assignment as encoding a melatonin receptor.

2 by melatonin is mediated via a G(i)-coupled melatonin receptor.

3 tigate the nature of the binding site of the melatonin receptor.

4 pendent of an effect on the classic membrane melatonin receptors.

5 have been identified including glutamate and melatonin receptors.

6 se binding sites represent G protein-coupled melatonin receptors.

7 nuclear receptors, such as Rev-ErbA and the melatonin receptors.

8 the opsins share a common ancestor with the melatonin receptors.

9 activity occurs through activation of MT(2) melatonin receptors.

10 through activation of G protein-coupled MT2 melatonin receptors.

11 control cells suggesting a partial role for melatonin receptors.

12 ly increases photoreceptor responses through melatonin receptors.

13 tional assays on recombinant mt(1) and MT(2) melatonin receptors.

14 to differences in the density or affinity of melatonin receptors.

15 and depression/anxiety-related behavior in a melatonin receptor 1 (MT1)-dependent manner.

16 We report that melatonin receptor 1 inhibits mobilization of L1 in cult

17 ifferentially methylated CpG site within the melatonin receptor 1A (MTNR1A) gene mediates the effect

18 Variants in the gene encoding melatonin receptor 1B (MTNR1B) were consistently associa

19 The T2D risk variant in the melatonin receptor 1B gene (MTNR1B) predicted risk of PO

20 ell as the duration of single calls, and (3) melatonin receptor 1b is highly expressed in evolutionar

21 anelle transport and signaling downstream of melatonin receptor [3, 4].

22 duced phase shifts of locomotor behavior and melatonin receptors activate G-protein-coupled inwardly

23 at this protective capacity may also rely on melatonin receptor activation.

24 ity of our previous 5-HT2C agonists with the melatonin receptor agonist tasimelteon and the putative

25 ramelteon, a potent and clinically relevant melatonin receptor agonist, significantly affect the neu

26 Finally, application of ramelteon, a potent melatonin receptor agonist, significantly decreased firi

27 nce) of once-daily tasimelteon, a novel dual-melatonin receptor agonist.

28 as designed to investigate whether selective melatonin receptor-agonist ramelteon may influence survi

29 s, antihypertensive drugs, antiviral agents, melatonin receptor agonists, anticholesterol and antican

30 an rhythms by activation of a membrane-bound melatonin receptor and strongly suggests that this effec

31 ction, at least in birds, since they express melatonin receptors and melatonin affects their metaboli

32 ulates dopamine release by the activation of melatonin receptors and that endogenous melatonin modula

33 larization-evoked calcium increases, and the melatonin receptor antagonist 4-P-PDOT blocked this effe

34 n of human blood with exogenous melatonin or melatonin receptor antagonist during the in situ perfusi

35 d this effect was blocked by the competitive melatonin receptor antagonist luzindole (100-1000 nM).

36 investigated by intravitreally injecting the melatonin receptor antagonist luzindole into rats.

37 reversed by perfusion of tumors in situ with melatonin receptor antagonist S-20928, pertussis toxin,

38 of both luzindole, a reference MT2-selective melatonin receptor antagonist, and melatonin.

39 Luzindole (1 microM), a competitive melatonin receptor antagonist, antagonized the effect of

40 1/1.0/10 mg/kg; mice: 1.0 mg/kg), ramelteon, melatonin receptor-antagonist luzindole, ramelteon + luz

41 Neither the selective MT2 melatonin receptor antagonists 4P-ADOT and 4P-PDOT (90 m

42 The addition of melatonin receptor antagonists abolishes the MT1 effect

43 Treatment with melatonin receptor antagonists at night dramatically imp

44 tonin in development is unknown, even though melatonin receptors appear to be more highly expressed i

45 Loss-of-function mutations in the melatonin receptor are associated with insulin resistanc

46 Moreover, receptors for serotonin and melatonin receptors are expressed in keratinocytes, mela

47 Although G protein-coupled MT1 and MT2 melatonin receptors are expressed in neurons of the mamm

48 Melatonin receptors are expressed in retinal photorecept

49 This study indicates that Mel1a and Mel1b melatonin receptors are expressed specifically in the Xe

50 in the pars distalis (PD) of the pituitary, melatonin receptors are localized in the pars tuberalis

51 Melatonin receptors bind and become activated by melaton

52 e, and luzindole, a competitive inhibitor of melatonin receptor binding, were examined for their abil

53 These modulatory effects were diminished by melatonin receptor blockade and pertussis toxin (PTX).

54 -min nicotine exposure; and (4). the role of melatonin receptors (by pertussis toxin inhibition) on n

55 In the present work, the mouse Mel(1b) melatonin receptor cDNA was isolated and characterized,

56 Eyes pretreated with the melatonin receptor competitive antagonist luzindole befo

57 ne rhythms in mammals; the data suggest that melatonin-receptor-containing cells in the pituitary gla

58 A pharmacological block of melatonin receptors delays neurogenesis and reduces neur

59 nsiderable amino acid sequence identity with melatonin receptors, does not bind melatonin and is curr

60 r plasma melatonin concentration and a lower melatonin receptor expression in the anterior cingular c

61 ification of 2-[125I]iodomelatonin and Mel1a melatonin receptor expression in the fetal leptomeninges

62 cent efforts to clone further members of the melatonin receptor family have led to the identification

63 Blockade of melatonin receptor function by pre-exposure to pertussis

64 ls, while among humans, polymorphisms in the melatonin receptor gene are associated with insulin resi

65 Melatonin receptors have been identified in several reti

66 Furthermore, hMT2-GFP melatonin receptors heterologously expressed in immortal

67 or 7-70 pg/mL) decreased the number of hMT2 melatonin receptors heterologously expressed in mammalia

68 onstrates the involvement of the MT2 (Mel1b) melatonin receptor in mediating phase advances of circad

69 The role of retinal melatonin receptors in modulating light-damage susceptib

70 ests that melatonin, acting through specific melatonin receptors in ocular tissues, plays a role in o

71 expression and signaling of MT(1) and MT(2) melatonin receptors in SCN2.2 cells.

72 ion of melatonin desensitizes endogenous MT2 melatonin receptors in the mammalian SCN thereby providi

73 These results suggest multiple roles for melatonin receptors in the regulation of astroglial func

74 The human ML1A melatonin receptor is expressed in the suprachiasmatic n

75 s demonstrated that mRNA for MT(1) and MT(2) melatonin receptors is expressed mostly in cells with ne

76 t variation in the number and/or location of melatonin receptors is the basis for individual differen

77 on of melatonin, combined with expression of melatonin receptors, is involved in the regulation of th

78 ctivity, and agonist behavior of these novel melatonin receptor ligands based on superposition models

79 erposition models guided the design of novel melatonin receptor ligands characterized by a 2-acylamin

80 To assess melatonin receptor localization in the OPL, double-label

81 super high affinity state of the human ML1A melatonin receptor may be the mechanism by which low con

82 Since the Mel1a melatonin receptor may transduce the major neurobiologic

83 Melatonin receptors mediate improvements of survival aft

84 pes will allow molecular dissection of other melatonin receptor-mediated responses.

85 r growth inhibition by melatonin involving a melatonin receptor-mediated suppression of cAMP levels,

86 However, the organization of the melatonin receptors mediating this action in the outer p

87 detected expression of the G protein-coupled melatonin receptor Mel1a, but not Mel1b.

88 the first time the expression of mt1 and MT2 melatonin receptor mRNA within the suprachiasmatic nucle

89 polymicrobial sepsis in rats, wild-type and melatonin receptor MT1/MT2 double knockout mice.

90 humans is associated with loss of the type 1 melatonin receptor (MT1).

91 ive effects of melatonin, while the membrane melatonin receptors (MT1 or MT2) did not change the acti

92 y1) or negatively (exemplified by the type 1 melatonin receptor, mt1).

93 New compounds were fully characterized at melatonin receptors (MT1R and MT2R), and results were ra

94 The decrease in MT2 melatonin receptor number induced by melatonin (300 pM f

95 the current status in the emerging field of melatonin receptor oligomerization are critically discus

96 wn about the influence of native MT1 and MT2 melatonin receptors on neuronal melatonin signaling.

97 Targeted disruption of the Mel(1a) melatonin receptor prevents some, but not all, responses

98 MT(1) and MT(2) melatonin receptor proteins are expressed in both rat SC

99 ression of the Mel(1a), Mel(1b), and Mel(1c) melatonin receptor proteins in ocular tissues was examin

100 from both chick and mouse brains, expressed melatonin receptor proteins.

101 onclude that SCN2.2 cells express functional melatonin receptors, providing an in vitro model to unve

102 Ramelteon is a novel MT1 and MT2 melatonin receptor selective agonist recently approved f

103 way and agonist regulation of the human ML1A melatonin receptor stably expressed in Chinese hamster o

104 We conclude that the MT2 melatonin receptor subtype is a novel therapeutic target

105 study was to determine the expression of the melatonin receptor subtype proteins in chick ocular tiss

106 that this effect is mediated through the MT2 melatonin receptor subtype within the circadian timing s

107 The other melatonin receptor subtype, the Mel1b receptor, is expre

108 Results of this study show that all three melatonin receptor subtypes are expressed in retinal and

109 Two high-affinity, G protein-coupled melatonin receptor subtypes have been identified in mamm

110 Mice with targeted disruption of melatonin receptor subtypes will allow molecular dissect

111 The Xenopus melatonin receptor thus cannot accommodate an N-n-alkyl

112 e that the pattern of expression of neuronal melatonin receptor types in different brain areas and ce

113 ocal immunohistochemistry for Mel1a or Mel1b melatonin receptors was performed in combination with ma

114 o as H9, is clearly related to high-affinity melatonin receptors yet unable to bind this hormone.